ストックスクリーナーアプリを入手
1.14
4.20%
-0.05
前日終値:
$1.19
開ける：
$1.19
24時間の取引高:
338.87K
Relative Volume:
1.40
時価総額：
$10.78M
収益：
当期純損益:
$-20.84M
株価収益率:
-0.1546
EPS:
-7.3739
ネットキャッシュフロー:
$-18.59M
1週間 パフォーマンス:
-21.38%
1か月 パフォーマンス:
-51.49%
6か月 パフォーマンス:
-62.13%
1年 パフォーマンス:
-76.00%
1日の値動き範囲:
$1.12
$1.28
1週間の範囲:
$1.12
$1.60
52週間の値動き範囲:
$1.12
$5.069
Cellectar Biosciences Inc Stock (CLRB) Company Profile
名前
Cellectar Biosciences Inc
セクター
電話
(608) 441-8120
住所
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
1.14 | 10.78M | 0 | -20.84M | -18.59M | -7.3739 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-15 | 開始されました | Ladenburg Thalmann | Buy |
| 2026-03-10 | アップグレード | Maxim Group | Hold → Buy |
| 2024-12-05 | 再開されました | Ladenburg Thalmann | Buy |
| 2020-07-01 | 開始されました | Oppenheimer | Outperform |
| 2020-01-21 | 再開されました | ROTH Capital | Buy |
| 2019-09-13 | 開始されました | ROTH Capital | Buy |
| 2016-12-21 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Cellectar Biosciences Inc (CLRB) 最新ニュース
Cancer treatment responses lasted a median 16 months in Cellectar's study - Stock Titan
Cellectar Biosciences Presents Compelling Efficacy Data - GlobeNewswire
Cellectar Biosciences Share PriceCLRB, RNS News, Articles, Quotes, & Charts (NASDAQ:CLRB) - Proactive financial news
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia - Investing News Network
A cancer drug produced responses in 87.5% of patients resistant to a prior cancer treatment - Stock Titan
Cellectar Biosciences to Present Compelling Efficacy Data - GlobeNewswire
Cellectar Biosciences (CLRB) Edges Lower: Support Holds Near $2.41 Amid ConsolidationWeekly Profile - dars.gov.et
Cellectar Biosciences (CLRB) Edges Lower: Support Holds Near $2.41 Amid ConsolidationFibonacci Fan - dars.gov.et
Balyasny Asset Management L.P. Initiates New Position in Cellect - GuruFocus
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript - AOL.com
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer TherapySlideshow (NASDAQ:CLRB) 2026-08-18 - Seeking Alpha
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlig - GuruFocus
CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 4.84% Stock RallyEarnings Revision Upgrade - vinanet.vn
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ... - Yahoo Finance
Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake - Stock Titan
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar - TipRanks
Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings - Stock Titan
Cellectar Biosciences (CLRB) investor discloses 9.99% stake via stock and warrants - Stock Titan
Ladenburg Thalmann Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants - Stock Titan
Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake - Stock Titan
Cellectar Biosciences Releases Q2 2026 Financial Results - AlphaStreet
CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss of $1.30 Per Share as Development Focus Intensifies - vinanet.vn
Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens - Investing.com
CLRB: Positive clinical results, robust financing, and regulatory momentum drive pipeline advancement - TradingView
Cellectar Biosciences Q2 2026 Earnings Call Transcript - Benzinga
Cellectar Q2 net loss widens 28% to $6.9M, misses EPS estimate - scanx.trade
Cellectar Biosciences reports Q2 2026 net loss $6.9M, cash $34.0M; advances iopofosine Phase 3 - TradingView
CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM - TradingView
Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M - Stock Titan
Cellectar Biosciences Q2 net loss widens on higher R&D costs - TradingView
Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing - Stock Titan
Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary - TradingView
Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk - Stock Titan
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Yahoo Finance
Cellectar Biosciences Reports Q2 2026 Results and Advances Phase 3 Iopofosine I 131 Program in Waldenström Macroglobulinemia | CLRB Stock News - Quiver Quantitative
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - GlobeNewswire
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Consensus by 32.39% as Pre-Revenue Pipeline AdvancesBuyback Announcement Report - vinanet.vn
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Consensus by 32.39% as Pre-Revenue Pipeline AdvancesGuidance Downgrade Alert - dars.gov.et
Cellectar Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Empery Asset Management, LP Initiates Position in Cellectar Bios - GuruFocus
Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured - Stock Titan
Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18 - Stock Titan
Cellectar BioSciences (CLRB.US) will release its earnings report before the market opens on August 13. - Moomoo
Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants - Stock Titan
CLRB Q1 2026 Earnings: 32.4% EPS Beat Signals Cost Discipline Amid Pipeline ProgressBanking Earnings Report - vinanet.vn
Cellectar Biosciences Inc (CLRB) 財務データ
収益
当期純利益
現金流量
EPS
Cellectar Biosciences Inc (CLRB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer |
May 07 '26 |
Buy |
2.88 |
8,680 |
24,998 |
20,318 |
| NEIS JOHN | Director |
Dec 12 '25 |
Sale |
3.70 |
198 |
732 |
10 |
4.22%
大文字化:
|
ボリューム (24 時間):